ILC Therapeutics is an early-stage biotech company that focuses on developing novel peptide therapeutics to modulate the Innate Immune System. Their hybrid interferon medicines, called ILCT 1001 and ILCT 1002, have shown promise in affecting key cells involved in cancer, atopic dermatitis, and psoriasis. With several patents in this area, ILC Therapeutics aims to improve patient outcomes and find a cure for various diseases, including COVID-19.